Chemical Formula: C4H9NO2S

Chemical Formula C4H9NO2S

Found 38 metabolite its formula value is C4H9NO2S

S-Methylcysteine

S-Methyl-L-cysteine, substrate for methionine sulfoxide reductase A

C4H9NO2S (135.0353974)


S-methylcysteine is a cysteine derivative that is L-cysteine in which the hydrogen attached to the sulfur is replaced by a methyl group. It has a role as a human urinary metabolite and a plant metabolite. It is a tautomer of a S-methylcysteine zwitterion. S-Methyl-L-cysteine is a natural product that acts as a substrate in the catalytic antioxidant system mediated by methionine sulfoxide reductase A (MSRA), with antioxidative, neuroprotective, and anti-obesity activities.

   

Homocysteine

(2S)-2-amino-4-sulfanylbutanoic acid

C4H9NO2S (135.0353974)


A high level of blood serum homocysteine is a powerful risk factor for cardiovascular disease. Unfortunately, one study which attempted to decrease the risk by lowering homocysteine was not fruitful. This study was conducted on nearly 5000 Norwegian heart attack survivors who already had severe, late-stage heart disease. No study has yet been conducted in a preventive capacity on subjects who are in a relatively good state of health.; Elevated levels of homocysteine have been linked to increased fractures in elderly persons. The high level of homocysteine will auto-oxidize and react with reactive oxygen intermediates and damage endothelial cells and has a higher risk to form a thrombus. Homocysteine does not affect bone density. Instead, it appears that homocysteine affects collagen by interfering with the cross-linking between the collagen fibers and the tissues they reinforce. Whereas the HOPE-2 trial showed a reduction in stroke incidence, in those with stroke there is a high rate of hip fractures in the affected side. A trial with 2 homocysteine-lowering vitamins (folate and B12) in people with prior stroke, there was an 80\\\\\\% reduction in fractures, mainly hip, after 2 years. Interestingly, also here, bone density (and the number of falls) were identical in the vitamin and the placebo groups.; Homocysteine is a sulfur-containing amino acid that arises during methionine metabolism. Although its concentration in plasma is only about 10 micromolar (uM), even moderate hyperhomocysteinemia is associated with increased incidence of cardiovascular disease and Alzheimers disease. Elevations in plasma homocysteine are commonly found as a result of vitamin deficiencies, polymorphisms of enzymes of methionine metabolism, and renal disease. Pyridoxal, folic acid, riboflavin, and Vitamin B(12) are all required for methionine metabolism, and deficiency of each of these vitamins result in elevated plasma homocysteine. A polymorphism of methylenetetrahydrofolate reductase (C677T), which is quite common in most populations with a homozygosity rate of 10-15 \\\\\\%, is associated with moderate hyperhomocysteinemia, especially in the context of marginal folate intake. Plasma homocysteine is inversely related to plasma creatinine in patients with renal disease. This is due to an impairment in homocysteine removal in renal disease. The role of these factors, and of modifiable lifestyle factors, in affecting methionine metabolism and in determining plasma homocysteine levels is discussed. Homocysteine is an independent cardiovascular disease (CVD) risk factor modifiable by nutrition and possibly exercise. Homocysteine was first identified as an important biological compound in 1932 and linked with human disease in 1962 when elevated urinary homocysteine levels were found in children with mental retardation. This condition, called homocysteinuria, was later associated with premature occlusive CVD, even in children. These observations led to research investigating the relationship of elevated homocysteine levels and CVD in a wide variety of populations including middle age and elderly men and women with and without traditional risk factors for CVD. (PMID 17136938, 15630149); Homocysteine is an amino acid with the formula HSCH2CH2CH(NH2)CO2H. It is a homologue of the amino acid cysteine, differing by an additional methylene (-CH2-) group. It is biosynthesized from methionine by the removal of its terminal C? methyl group. Homocysteine can be recycled into methionine or converted into cysteine with the aid of B-vitamins.; Studies reported in 2006 have shown that giving vitamins [folic acid, B6 and B12] to reduce homocysteine levels may not quickly offer benefit, however a significant 25\\\\\\% reduction in stroke was found in the HOPE-2 study even in patients mostly with existing serious arterial decline although the overall death rate was not significantly changed by the intervention in the trial. Clearly, reducing homocysteine does not quickly repair existing... Homocysteine (CAS: 454-29-5) is a sulfur-containing amino acid that arises during methionine metabolism. Although its concentration in plasma is only about 10 micromolar (uM), even moderate hyperhomocysteinemia is associated with an increased incidence of cardiovascular disease and Alzheimers disease. Elevations in plasma homocysteine are commonly found as a result of vitamin deficiencies, polymorphisms of enzymes of methionine metabolism, and renal disease. It has been identified as a uremic toxin according to the European Uremic Toxin Working Group (PMID: 22626821). Pyridoxal, folic acid, riboflavin, and vitamin B(12) are all required for methionine metabolism, and deficiency of each of these vitamins result in elevated plasma homocysteine. A polymorphism of methylenetetrahydrofolate reductase (C677T), which is quite common in most populations with a homozygosity rate of 10-15 \\\\\\%, is associated with moderate hyperhomocysteinemia, especially in the context of marginal folate intake. Plasma homocysteine is inversely related to plasma creatinine in patients with renal disease. This is due to an impairment in homocysteine removal in renal disease. The role of these factors, and of modifiable lifestyle factors, in affecting methionine metabolism and in determining plasma homocysteine levels is discussed. Homocysteine is an independent cardiovascular disease (CVD) risk factor modifiable by nutrition and possibly exercise. Homocysteine was first identified as an important biological compound in 1932 and linked with human disease in 1962 when elevated urinary homocysteine levels were found in children with mental retardation. This condition, called homocystinuria, was later associated with premature occlusive CVD, even in children. These observations led to research investigating the relationship of elevated homocysteine levels and CVD in a wide variety of populations including middle age and elderly men and women with and without traditional risk factors for CVD (PMID: 17136938 , 15630149). Moreover, homocysteine is found to be associated with cystathionine beta-synthase deficiency, cystathioninuria, methylenetetrahydrofolate reductase deficiency, and sulfite oxidase deficiency, which are inborn errors of metabolism. [Spectral] L-Homocysteine (exact mass = 135.0354) and L-Valine (exact mass = 117.07898) were not completely separated on HPLC under the present analytical conditions as described in AC$XXX. Additionally some of the peaks in this data contains dimers and other unidentified ions. Homocysteine is biosynthesized naturally via a multi-step process.[9] First, methionine receives an adenosine group from ATP, a reaction catalyzed by S-adenosyl-methionine synthetase, to give S-adenosyl methionine (SAM-e). SAM-e then transfers the methyl group to an acceptor molecule, (e.g., norepinephrine as an acceptor during epinephrine synthesis, DNA methyltransferase as an intermediate acceptor in the process of DNA methylation). The adenosine is then hydrolyzed to yield L-homocysteine. L-Homocysteine has two primary fates: conversion via tetrahydrofolate (THF) back into L-methionine or conversion to L-cysteine.[10] Biosynthesis of cysteine Mammals biosynthesize the amino acid cysteine via homocysteine. Cystathionine β-synthase catalyses the condensation of homocysteine and serine to give cystathionine. This reaction uses pyridoxine (vitamin B6) as a cofactor. Cystathionine γ-lyase then converts this double amino acid to cysteine, ammonia, and α-ketobutyrate. Bacteria and plants rely on a different pathway to produce cysteine, relying on O-acetylserine.[11] Methionine salvage Homocysteine can be recycled into methionine. This process uses N5-methyl tetrahydrofolate as the methyl donor and cobalamin (vitamin B12)-related enzymes. More detail on these enzymes can be found in the article for methionine synthase. Other reactions of biochemical significance Homocysteine can cyclize to give homocysteine thiolactone, a five-membered heterocycle. Because of this "self-looping" reaction, homocysteine-containing peptides tend to cleave themselves by reactions generating oxidative stress.[12] Homocysteine also acts as an allosteric antagonist at Dopamine D2 receptors.[13] It has been proposed that both homocysteine and its thiolactone may have played a significant role in the appearance of life on the early Earth.[14] L-Homocysteine. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=454-28-4 (retrieved 2024-06-29) (CAS RN: 6027-13-0). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0). DL-Homocysteine is a weak neurotoxin, and can affect the production of kynurenic acid in the brain. DL-Homocysteine is a weak neurotoxin, and can affect the production of kynurenic acid in the brain. L-Homocysteine, a homocysteine metabolite, is a homocysteine that has L configuration. L-Homocysteine induces upregulation of cathepsin V that mediates vascular endothelial inflammation in hyperhomocysteinaemia[1][2].

   

DL-Homocysteine

2-Amino-4-mercaptobutyric acid

C4H9NO2S (135.0353974)


DL-Homocysteine is a weak neurotoxin, and can affect the production of kynurenic acid in the brain. DL-Homocysteine is a weak neurotoxin, and can affect the production of kynurenic acid in the brain.

   

S-methylcysteine

S-methylcysteine, hydrochloride, (L-Cys)-isomer

C4H9NO2S (135.0353974)


Methylcysteine is one of the identified number of bioactive substances in garlic that are water soluble (PMID 16484549). It has been suggested that the use of these organosulfur agents derived from garlic could protect partially oxidized and glycated LDL or plasma against further oxidative and glycative deterioration, which might benefit patients with diabetic-related vascular diseases (PMID 15161248). It may also exert some chemopreventive effects on chemical carcinogenesis. However, it should be borne in mind that may also demonstrate promotion potential, depending on the organ examined (PMID 9591199). Methylcystein is a biomarker for the consumption of dried and cooked beans. S-n-methylcysteine, also known as (2r)-2-amino-3-(methylsulfanyl)propanoic acid or 3-(methylthio)-L-alanine, is a member of the class of compounds known as L-cysteine-s-conjugates. L-cysteine-s-conjugates are compounds containing L-cysteine where the thio-group is conjugated. S-n-methylcysteine is soluble (in water) and a moderately acidic compound (based on its pKa). S-n-methylcysteine can be found in soft-necked garlic, which makes S-n-methylcysteine a potential biomarker for the consumption of this food product. S-n-methylcysteine can be found primarily in blood and urine. S-Methyl-L-cysteine is a natural product that acts as a substrate in the catalytic antioxidant system mediated by methionine sulfoxide reductase A (MSRA), with antioxidative, neuroprotective, and anti-obesity activities.

   

Mecysteine

methyl 2-amino-3-sulfanylpropanoate

C4H9NO2S (135.0353974)


   

N-Methylcysteine

2-(Methylamino)-3-sulphanylpropanoic acid

C4H9NO2S (135.0353974)


   

Thiomorpholine 1,1-dioxide

1lambda6-thiomorpholine-1,1-dione

C4H9NO2S (135.0353974)


   

S-N-Methylcysteine

S-methylcysteine, hydrochloride, (L-Cys)-isomer

C4H9NO2S (135.0353974)


S-n-methylcysteine, also known as (2r)-2-amino-3-(methylsulfanyl)propanoic acid or 3-(methylthio)-L-alanine, is a member of the class of compounds known as L-cysteine-s-conjugates. L-cysteine-s-conjugates are compounds containing L-cysteine where the thio-group is conjugated. S-n-methylcysteine is soluble (in water) and a moderately acidic compound (based on its pKa). S-n-methylcysteine can be found in soft-necked garlic, which makes S-n-methylcysteine a potential biomarker for the consumption of this food product. S-n-methylcysteine can be found primarily in blood and urine. S-Methyl-L-cysteine is a natural product that acts as a substrate in the catalytic antioxidant system mediated by methionine sulfoxide reductase A (MSRA), with antioxidative, neuroprotective, and anti-obesity activities.

   

3-(METHYLTHIO)ALANINE

3-(METHYLTHIO)ALANINE

C4H9NO2S (135.0353974)


   

2-amino-3-sulfanylbutanoic acid

2-amino-3-sulfanylbutanoic acid

C4H9NO2S (135.0353974)


   

methyl D-cysteinate

methyl D-cysteinate

C4H9NO2S (135.0353974)


   

L-Homocysteine

DL-Homocysteine

C4H9NO2S (135.0353974)


A homocysteine that has L configuration. L-Homocysteine, a homocysteine metabolite, is a homocysteine that has L configuration. L-Homocysteine induces upregulation of cathepsin V that mediates vascular endothelial inflammation in hyperhomocysteinaemia[1][2].

   

Homocysteine

DL-Homocysteine

C4H9NO2S (135.0353974)


A sulfur-containing amino acid consisting of a glycine core with a 2-mercaptoethyl side-chain. MS2 deconvoluted using MS2Dec from all ion fragmentation data, MetaboLights identifier MTBLS1040; FFFHZYDWPBMWHY_STSL_0127_Homocysteine_8000fmol_180506_S2_LC02_MS02_123; Spectrum acquired as described in Naz et al 2017 PMID 28641411. Preparation and submission to MassBank of North America by Chaleckis R. and Tada I. DL-Homocysteine is a weak neurotoxin, and can affect the production of kynurenic acid in the brain. DL-Homocysteine is a weak neurotoxin, and can affect the production of kynurenic acid in the brain. L-Homocysteine, a homocysteine metabolite, is a homocysteine that has L configuration. L-Homocysteine induces upregulation of cathepsin V that mediates vascular endothelial inflammation in hyperhomocysteinaemia[1][2].

   

Methylcysteine

S-Methyl-L-cysteine

C4H9NO2S (135.0353974)


S-Methyl-L-cysteine is a natural product that acts as a substrate in the catalytic antioxidant system mediated by methionine sulfoxide reductase A (MSRA), with antioxidative, neuroprotective, and anti-obesity activities.

   

S-Methyl-L-cysteine

S-Methyl-L-cysteine

C4H9NO2S (135.0353974)


S-Methyl-L-cysteine is a natural product that acts as a substrate in the catalytic antioxidant system mediated by methionine sulfoxide reductase A (MSRA), with antioxidative, neuroprotective, and anti-obesity activities.

   

mecysteine

mecysteine

C4H9NO2S (135.0353974)


C78273 - Agent Affecting Respiratory System > C74536 - Mucolytic Agent D019141 - Respiratory System Agents > D005100 - Expectorants

   

3-Thiophenamine,tetrahydro-, 1,1-dioxide

3-Thiophenamine,tetrahydro-, 1,1-dioxide

C4H9NO2S (135.0353974)


   

S-methyl-D-cysteine

S-methyl-D-cysteine

C4H9NO2S (135.0353974)


   

1-Methylcyclopropanesulfonamide

1-Methylcyclopropanesulfonamide

C4H9NO2S (135.0353974)


   

2H-1,2-Thiazine,tetrahydro-, 1,1-dioxide

2H-1,2-Thiazine,tetrahydro-, 1,1-dioxide

C4H9NO2S (135.0353974)


   

3-(Methylsulfonyl)azetidine

3-(Methylsulfonyl)azetidine

C4H9NO2S (135.0353974)


   

Thiomorpholine 1,1-dioxide

Thiomorpholine 1,1-dioxide

C4H9NO2S (135.0353974)


   

D-Homocysteine

(R)-2-AMINO-4-MERCAPTOBUTANOIC ACID

C4H9NO2S (135.0353974)


   

1,4-Oxathiane, 4,4-dihydro-4-imino-, 4-oxide

1,4-Oxathiane, 4,4-dihydro-4-imino-, 4-oxide

C4H9NO2S (135.0353974)


   

2-[(2-hydroxyethyl)thio]acetamide

2-[(2-hydroxyethyl)thio]acetamide

C4H9NO2S (135.0353974)


   

N-Allylmethanesulfonamide

N-Allylmethanesulfonamide

C4H9NO2S (135.0353974)


   

Ethenesulfonic acid dimethylamide

Ethenesulfonic acid dimethylamide

C4H9NO2S (135.0353974)


   

cyclobutanesulfonamide

cyclobutanesulfonamide

C4H9NO2S (135.0353974)


   

(3R)-3-amino-4-sulfanylbutanoic acid

(3R)-3-amino-4-sulfanylbutanoic acid

C4H9NO2S (135.0353974)


   

(2S)-2-azaniumyl-4-sulfanylbutanoate

(2S)-2-azaniumyl-4-sulfanylbutanoate

C4H9NO2S (135.0353974)


   

(2R)-2-azaniumyl-3-(methylsulfanyl)propanoate

(2R)-2-azaniumyl-3-(methylsulfanyl)propanoate

C4H9NO2S (135.0353974)


   

(2S)-2-azaniumyl-3-methylsulfanylpropanoate

(2S)-2-azaniumyl-3-methylsulfanylpropanoate

C4H9NO2S (135.0353974)


   

(2R)-2-azaniumyl-4-sulfanylbutanoate

(2R)-2-azaniumyl-4-sulfanylbutanoate

C4H9NO2S (135.0353974)


   

2-Ammonio-4-sulfanylbutanoate

2-Ammonio-4-sulfanylbutanoate

C4H9NO2S (135.0353974)


   

S-methylcysteine zwitterion

S-methylcysteine zwitterion

C4H9NO2S (135.0353974)


An S-alkyl-L-cysteine zwitterion obtained by transfer of a proton from the carboxy to the amino group of S-methylcysteine; major species at pH 7.3.

   

homocysteine zwitterion

homocysteine zwitterion

C4H9NO2S (135.0353974)


An amino acid zwitterion of homocysteine arising from transfer of a proton from the carboxy to the amino group; major species at pH 7.3.

   

L-homocysteine zwitterion

L-homocysteine zwitterion

C4H9NO2S (135.0353974)


An amino acid zwitterion arising from transfer of a proton from the carboxy to the amino group of L-homocysteine; major species at pH 7.3.

   

S-methylcysteine

S-methylcysteine

C4H9NO2S (135.0353974)


A cysteine derivative that is L-cysteine in which the hydrogen attached to the sulfur is replaced by a methyl group.